Search

Meet YoungEHA leaders Verena and Heiko

By Dr. Fabienne Lucas, MD PhD, YoungEHA Committee.

Read more

BENIGN HEMATOLOGY in 2023 and beyond

The term "benign hematology" has traditionally been used to refer to non-malignant blood disorders. However, over the past few years, questions have been raised as to the appropriate nomenclature for this category of diseases.

Read more

EU calls for proposal 2023

IntroductionHorizon Europe is the research and innovation programme of the EU for the period 2021-2027. The programme facilitates research collaboration and strengthens the impact of R&I in developing, supporting and implementing EU policies while tackling global challenges.

Read more

Join EHA and SIE and receive up to €50 discount on your EHA membership

We are pleased to inform you that EHA and the Società Italiana di Ematologia (SIE) have joined forces and are offering you the possibility of an EHA-SIE Joint Membership.

Read more

Lymphoid malignancies dissected in Warsaw

The EHA–PTHiT Tutorial on Lymphoid Malignancies was held on March 17-18, 2017 in Warsaw, Poland. 96% of meeting attendees were satisfied with the tutorial saying that their expectations are met.

Read more

EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe”

On September 15-17, 2022, the EHA-SWG Scientific Meeting “Developing a research agenda for transfusion in Europe” was successfully held at the Occidental Praha hotel in Prague, Czechia.

Read more

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis

EHA IN COLLABORATION WITH BALTIC SOCIETIES CONCLUDE THE FIRST HYBRID TUTORIAL MEETING IN EHA HISTORY!

 

EHA-Baltic Hematology Tutorial on Bleeding Disorders & Thrombosis
August 28 – 30, 2020
Virtual & Riga, Latvia 

Meeting Chairs:

Prof S Eichinger (European Hematology Association)
Prof S Lejniece (Latvian Society of…

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders in EU is €23 billion

In Europe blood disorders affect around 80 million people. The total cost of blood disorders consists of healthcare expenditure (€15. 6 billion), productivity loss due to illness and mortality (€5. 6 billion), and the costs of informal care (€1.

Read more